Bayer initiates OCEANIC AFINA phase III study of asundexian in patients with AF ineligible for oral anticoagulant treatment

Press/Media

Period	7 Nov 2023

Media coverage

Title	Bayer initiates OCEANIC AFINA phase III study of asundexian in patients with AF ineligible for oral anticoagulant treatment
Media name/outlet	PharmaBiz
Country/Territory	India
Date	7/11/23
URL	ct.moreover.com/?a=52265455219&p=1gw&v=1&x=PnNYwhhljKtRTXbK-eDIKg
Persons	Roxana Mehran,